Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants
Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearanceEnrollment for Phase 1/2a trial has already startedUpcoming trial is first time a psilocybin analog will be evaluated for MDD treatmentStudies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the…